Variant-Level Functional Classification of Monoallelic TP53 Mutations Refines Prognostic Stratification in Myelodysplastic Neoplasms Beyond Allelic Status
Preprint
Abstract
TP53 mutations represent one of the strongest adverse prognostic factors in myelodysplastic neoplasms (MDS). While multi-hit TP53 ( TP53 multiHit ) alterations uniformly lead to very poor outcomes, the prognostic relevance of monoallelic TP53 ( TP53 mono ) mutations remains controversial. TP53 variants can cause loss-of-function, dominant-negative, or gain-of-function effects. We hypothesized that functional heterogeneity among TP53 variants contributes to the variable clinical behavior observed in monoallelic TP53 -mutated MDS. Therefore, we analyzed pretreatment samples from 4,505 patients with MDS from two independent cohorts (IWG, n=3,173; J-MDS, n=1,332), including 271 patients with TP53 mono and 499 with TP53 multiHit . Functional annotation of TP53 variants was performed using a previously published phenotype score (PS) derived from saturation mutagenesis screens, capturing dominant-negative and loss-of-function effects. Median overall survival (OS) differed significantly by TP53 allelic state ( TP53 wild-type ( TP53 wt ) 42.4 months; TP53 mono 22.9 months; TP53 multiHit 9.2 months; p < 0.001). Within the TP53 mono subgroup, functional annotation identified marked heterogeneity. Patients with high PS (≥7) showed significantly inferior OS compared with those with low PS (median OS: 13.8 vs. 39.2 months; HR 1.68, 95% CI 1.16-2.42; p = 0.006), particularly for IPSS-R and IPSS-M low-risk cases. Combining PS and variant allele frequency (VAF) further improved risk stratification. TP53 mono patients with PS ≥7 and VAF ≥22% had outcomes comparable to TP53 multiHit (median OS: 8.8, p = 0.2), whereas those with PS TP53 wt (median OS: 49.7, p = 0.9). Overall, functional annotation of TP53 variants refines prognostication in TP53 mono -mutated MDS and may enhance individualized risk assessment.Keywords
This publication has 28 references indexed in Scilit:
- Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progressionBlood Neoplasia, 2024
- Targeting p53 pathways: mechanisms, structures and advances in therapySignal Transduction and Targeted Therapy, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- The p53 network: cellular and systemic DNA damage responses in cancer and agingTrends in Genetics, 2022
- TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsLeukemia, 2019
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromesLeukemia, 2015
- Integrated molecular analysis of adult T cell leukemia/lymphomaNature Genetics, 2015
- p53 in health and diseaseNature Reviews Molecular Cell Biology, 2007
- Surfing the p53 networkNature, 2000
- Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformationCell, 1991